Bell Rock Capital’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Bell Rock Capital’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-13,035	Closed	-$678K	–	364
2019 Q2	$678K	Sell	13,035 -8,495	-39%	-$423K	0.6%	35
2019 Q1	$1.2M	Buy	21,530 +5,075	+31%	+$273K	0.69%	43
2018 Q4	$691K	Buy	16,455 +4,030	+32%	+$210K	0.46%	51
2018 Q3	$867K	Sell	12,425 -925	-7%	-$60.5K	0.43%	57
2018 Q2	$761K	Sell	13,350 -4,775	-26%	-$260K	0.38%	60
2018 Q1	$1M	Buy	18,125 +6,700	+59%	+$401K	0.53%	50
2017 Q4	$640K	Buy	11,425 +325	+3%	+$18.3K	0.35%	59
2017 Q3	$677K	Sell	11,100 -3,000	-21%	-$171K	0.39%	61
2017 Q2	$754K	Buy	14,100 +2,400	+21%	+$117K	0.46%	57
2017 Q1	$563K	Buy	11,700 +1,700	+17%	+$79K	0.52%	39
2016 Q4	$400K	Buy	+10,000	New	+$427K	0.42%	49

Other funds holding BIB

CIC

Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

SBIA

Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

CAL

Capital Analysts LLC Fort Washington, Pennsylvania $3.81B AUM 15.52% 1-Year Est. Return

Bell Rock Capital's BIB Position: Q3 2019 in Review

Bell Rock Capital sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2019, closing a stake of 13,035 shares — an estimated $678K sold.

Bell Rock Capital first reported a position in BIB in Q4 2016 and held it in 11 quarters. The position peaked at $1.2M in Q1 2019. 25 funds tracked by Wall St. Rank hold BIB as of Q3 2019.

Bell Rock Capital reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2019 after selling out during the quarter.
Bell Rock Capital sold 13,035 ProShares Ultra NASDAQ Biotechnology shares in Q3 2019, an estimated $678K.
Bell Rock Capital first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2016 and held it in 11 quarters.
Bell Rock Capital's ProShares Ultra NASDAQ Biotechnology position peaked at $1.2M in Q1 2019.
25 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2019.

Based on Bell Rock Capital's 13F filing for Q3 2019, filed 7 Nov 2019.